MedWatch

Novo’s R&D chief: Semaglutide wins out every time

Novo Nordisk's major pipeline hope semaglutide has bested pretty much every major diabetes drug on the market in head-to-head studies, says CSO Mads Krogsgaard Thomsen. But the group will still have to beat out two more products before the GLP-1 analogue can be seen as the king of the clinic.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Lægemiddelstyrelsen er skuffet, men glad for bronzen

Lægemiddelstyrelsens direktør Thomas Senderovitz er skuffet over, at København ikke skal huse EMA, men også stolt over at have snuppet "bronzemedaljerne". Han påpeger dog også, at der ligger masser af arbejde forude i forbindelse med flytningen af lægemiddelagenturet.

Latest Top picks in English

Related articles